📰 Merck Sharp News
Page 146 - Merck Sharp News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Merck Sharp. Real-time updates on events, politics, business and more.
February 4, 2021
chetanFebruary 4, 2021 CNS Therapeutics CNS Therapeutics Market Report Coverage: Key Growth Factors & Challenges, Segmentation & Regional Outlook, Top Industry Trends & Opportunities, Competition Analysis, COVID-19 Impact Analysis & Projected Recovery, and Market Sizing & Forecast Considering COVID-19 Impact and Increasing Demand of global market, Big Market Research has recently Added a research report titled, “ CNS Therapeutics Market “. This report has been prepared by knowl...
February 3, 2021
Gardasil Lawsuit Alleges Vaccine Caused Seizure Disorder, Infertility From: The national law firm of Baum Hedlund Aristei & Goldman has filed a Gardasil lawsuit against Merck alleging the multinational pharmaceutical corporation misled regulators and the public about the ...
February 2, 2021
Peripheral T-cell Lymphoma Market to exhibit a CAGR of 9.46% during the forecast period of 2020-2030, announces DelveInsight LAS VEGAS, Feb. 2, 2021 /PRNewswire/ -- DelveInsights " Peripheral T-Cell Lymphoma (PTCL) Market" report provides an absolute comprehension of the PTCL, historical and forecasted epidemiology and the Peripheral T-Cell Lymphoma market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Peripheral T-Cell Lymphoma mar...
February 2, 2021
Amgen Reports Fourth Quarter And Full Year 2020 Financial Results News provided by Share this article Share this article THOUSAND OAKS, Calif., Feb. 2, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2020 versus comparable periods in 2019. Key results include: For the fourth quarter, total revenues increased 7% to $6.6 billion in comparison to the fourth quarter of 2019, driven by higher volume growth, partially offset by lower ne...
February 1, 2021
1Assistance Publique–Hôpitaux de Paris, Department of General Paediatrics, Paediatric Infectious Disease and Internal Medicine, Robert Debré University Hospital, Université de Paris, Paris, France 2ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France 3Université de Paris, INSERM UMR 1123, ECEVE, Paris, France 4Assistance Publique–Hôpitaux de Paris, Department of General Paediatrics and Paediatric Infectious Diseases, Necker-Enfants-Malades Universit...
January 29, 2021
In a law review article entitled “The Death of the Genus Claim,” 1 which published in the aftermath of the Federal Circuit decision in Idenix v. Gilead, 941 F.3d 1149 (Fed. Cir. 2019), the authors stated that, “in the past thirty years, there are virtually no significant examples of genus claims in the life science fields upheld on appeal as compliant with § 112(a) outside the unique context of . . . ‘interference” proceedings.’” The authors accused the Federal Circuit of “aba...
January 29, 2021
OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs WALTHAM, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) — OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced the appointment of Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affai...
January 28, 2021
The Global Heart Failure Drugs Market research report released by Data Bridge Market research provides the market segmentation based on type, market size, Product launches and applications. It identifies the global adoption of the products as one of the growth factors, driven by the availability of the product. The global research report gives the brief summary of the leading players operating in the market, their product offering, key developments, investments feasibility and returns. This G...
January 28, 2021
Merck & Co. Inc. and Merck Sharp & Dohme Corp.: Complaint Against Glenn H. Carlson ( Filing Fee $ 402 Receipt Number 0313-14853760.), Filed By Glenn H. Carlson. (attachments: # 1 Civil Cover Sheet Civil Cover Sheet, # 2 Certificate Of Service Merck & Co. Inc. /pos, # 3 Certificate Of Service McKesson Corp./pos, #4 Certificate Of Service Merck Sharp And Dohme Corp./Pos, # 5 Case Management Track Form Case Management Track Form, # 6 Designation Form Designation Form)(humphrey, Debra) Weekly News...
January 28, 2021
The Global Nanomedicine market research report released by Data Bridge Market research provides the market segmentation based on type, market size, Product launches and applications. It identifies the global adoption of the products as one of the growth factors, driven by the availability of the product. The global research report gives the brief summary of the leading players operating in the market, their product offering, key developments, investments feasibility and returns. This Global N...